| Michael W Mellon, PHD | |
|
3333 Burnet Avenue, Ml 5021, Cincinnati, OH 45229-3039 | |
| (513) 636-4225 | |
| (513) 636-2511 |
| Full Name | Michael W Mellon |
|---|---|
| Gender | Male |
| Speciality | Psychologist - Clinical |
| Location | 3333 Burnet Avenue, Cincinnati, Ohio |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023088804 | NPI | - | NPPES |
| 811579600 | Medicaid | MN | |
| 680011889 | Other | MN | RAILROAD MEDICARE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 103TC0700X | Psychologist - Clinical | 6611 (Ohio) | Primary |
| 103TC2200X | Psychologist - Clinical Child & Adolescent | LP4195 (Minnesota) | Secondary |
| Entity Name | Children's Hospital Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1609915784 PECOS PAC ID: 8426955733 Enrollment ID: O20031216000035 |
News Archive
In a promising development for cancer patients in the New York metropolitan area, the Long Island Jewish (LIJ) Medical Center Department of Radiation Medicine announced today that it will acquire an innovative new system called TrueBeam that offers a radically different approach to treating cancer with image-guided radiotherapy.
People with substance abuse disorders cost Medicaid hundreds of millions of dollars annually in medical care, suggesting that early interventions for substance abuse could not only improve outcomes but also save substantial amounts of money, according to a comprehensive study that examined records of nearly 150,000 people in six states.
Merck & Co., Inc., known as MSD outside the United States and Canada, and Pfizer Inc. today announced that they have entered into a worldwide (except Japan) collaboration agreement for the development and commercialization of Pfizer's ertugliflozin (PF-04971729), an investigational oral sodium glucose cotransporter (SGLT2) inhibitor being evaluated for the treatment of type 2 diabetes.
For completely endophytic kidney tumors, which grow inward, both open partial nephrectomy (OPN) and robotic partial nephrectomy (RPN) led to excellent patient outcomes in a recent study.
Watson Pharmaceuticals, Inc. today provided a detailed overview of its expanded global operations, enhanced supply chain capabilities and commercial and pipeline developments in its Brand and Generics businesses during an Investor Day meeting held in New York, NY.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Michael W Mellon, PHD 3333 Burnet Avenue, Ml 3015, Cincinnati, OH 45229-3039 Ph: (513) 636-4336 | Michael W Mellon, PHD 3333 Burnet Avenue, Ml 5021, Cincinnati, OH 45229-3039 Ph: (513) 636-4225 |
News Archive
In a promising development for cancer patients in the New York metropolitan area, the Long Island Jewish (LIJ) Medical Center Department of Radiation Medicine announced today that it will acquire an innovative new system called TrueBeam that offers a radically different approach to treating cancer with image-guided radiotherapy.
People with substance abuse disorders cost Medicaid hundreds of millions of dollars annually in medical care, suggesting that early interventions for substance abuse could not only improve outcomes but also save substantial amounts of money, according to a comprehensive study that examined records of nearly 150,000 people in six states.
Merck & Co., Inc., known as MSD outside the United States and Canada, and Pfizer Inc. today announced that they have entered into a worldwide (except Japan) collaboration agreement for the development and commercialization of Pfizer's ertugliflozin (PF-04971729), an investigational oral sodium glucose cotransporter (SGLT2) inhibitor being evaluated for the treatment of type 2 diabetes.
For completely endophytic kidney tumors, which grow inward, both open partial nephrectomy (OPN) and robotic partial nephrectomy (RPN) led to excellent patient outcomes in a recent study.
Watson Pharmaceuticals, Inc. today provided a detailed overview of its expanded global operations, enhanced supply chain capabilities and commercial and pipeline developments in its Brand and Generics businesses during an Investor Day meeting held in New York, NY.
› Verified 9 days ago
Gerald B Powell, PH.D Psychologist Medicare: Not Enrolled in Medicare Practice Location: 1118 Ryalnd Ave, Cincinnati, OH 45237 Phone: 513-242-3894 Fax: 440-243-6530 | |
Diane Patricia Castelli, PH.D. Psychologist Medicare: Medicare Enrolled Practice Location: 1101 Summit Rd, Cincinnati, OH 45237 Phone: 513-948-3600 | |
Heather Strong Harrison, PH.D. Psychologist Medicare: Medicare Enrolled Practice Location: 3333 Burnet Ave, Ml3015, Cincinnati, OH 45229 Phone: 513-636-4336 Fax: 513-636-7756 | |
Dr. Donna Marie Maier, PH.D. Psychologist Medicare: Not Enrolled in Medicare Practice Location: 743 Reynard Ave, Cincinnati, OH 45231 Phone: 513-739-8705 Fax: 937-848-2080 | |
Rachelle Ann Sekerka, PHD Psychologist Medicare: Not Enrolled in Medicare Practice Location: 3200 Vine St, 116b, Cincinnati, OH 45220 Phone: 513-475-6402 | |
Dr. Molly W Nemann, EDD LICENSED PSYCHOL Psychologist Medicare: Not Enrolled in Medicare Practice Location: 2480 Walnut View Court, Cincinnati, OH 45230 Phone: 513-233-3998 Fax: 513-233-3998 | |
Dr. James Esmail, PSY.D Psychologist Medicare: Accepting Medicare Assignments Practice Location: 1101 Summit Rd, Cincinnati, OH 45237 Phone: 513-948-3721 |